{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:53:19Z","timestamp":1791355999074,"version":"4.3.1"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["EMDR\/SG\/15\/2025-01-05767"],"award-info":[{"award-number":["EMDR\/SG\/15\/2025-01-05767"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jsbmb.2026.107097","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:07:35Z","timestamp":1786115255000},"page":"107097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of steroidal molecules for targeted breast cancer therapy: Endocrine resistance and innovative drug design"],"prefix":"10.1016","volume":"265","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5269-547X","authenticated-orcid":false,"given":"Zahid Ahmad","family":"Dar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranju","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2026.107097_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jsbmb.2026.107097_bib2","first-page":"409","article-title":"Breast Cancer Statistics, 2011","volume":"61","author":"DeSantis","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jsbmb.2026.107097_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/humu.9082","article-title":"BRCA1 and BRCA2 in indian breast cancer patients","volume":"20","author":"Saxena","year":"2002","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.jsbmb.2026.107097_bib4","unstructured":"International Agency for Research on Cancer. World Cancer Report; 2020. Available from: https:\/\/www.iarc.who.int\/cards_page\/world-cancer-report\/ (accessed April 4, 2024)."},{"key":"10.1016\/j.jsbmb.2026.107097_bib5","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrc1211","article-title":"Aromatase inhibitors for breast cancer: lessons from the laboratory","volume":"3","author":"Johnston","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jsbmb.2026.107097_bib6","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2217\/fon.09.113","article-title":"Challenges in defining predictive markers for response to endocrine therapy in breast cancer","volume":"5","author":"Larionov","year":"2009","journal-title":"Future Oncol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib7","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/CM9.0000000000000745","article-title":"Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"133","author":"Shen","year":"2020","journal-title":"Chin. Med. J. (Engl. )"},{"key":"10.1016\/j.jsbmb.2026.107097_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","article-title":"Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets","volume":"60","author":"Liang","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jsbmb.2026.107097_bib10","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Panel members. strategies for subtypes--dealing with the diversity of breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.jsbmb.2026.107097_bib12","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jsbmb.2026.107097_bib14","first-page":"408","article-title":"Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer","volume":"54","author":"DeFriend","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107097_bib15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1634\/theoncologist.12-7-774","article-title":"Fulvestrant (Faslodex)\u2014how to make a good drug better","volume":"12","author":"Robertson","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.jsbmb.2026.107097_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/OTT.S400563","article-title":"Evaluating elacestrant in the management of ER-positive, HER2-negative advanced breast cancer: evidence to date","volume":"16","author":"Varella","year":"2023","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.jsbmb.2026.107097_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4062\/biomolther.2012.20.3.256","article-title":"Tamoxifen resistance in breast cancer","volume":"20","author":"Chang","year":"2012","journal-title":"Biomol. Ther."},{"key":"10.1016\/j.jsbmb.2026.107097_bib18","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.1200\/JCO.2007.11.3886","article-title":"Selective estrogen-receptor modulators and antihormonal resistance in breast cancer","volume":"25","author":"Jordan","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fendo.2019.00245","article-title":"Endocrine resistance in hormone receptor positive breast cancer\u2014from mechanism to therapy","volume":"10","author":"Rani","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","article-title":"Biological determinants of endocrine resistance in breast cancer","volume":"9","author":"Musgrove","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jsbmb.2026.107097_bib21","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0960-9776(11)70293-4","article-title":"Biological mechanisms and clinical implications of endocrine resistance in breast cancer","volume":"20","author":"Giuliano","year":"2011","journal-title":"Breast"},{"key":"10.1016\/j.jsbmb.2026.107097_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/or.2014.3190","article-title":"Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review)","volume":"32","author":"Viedma-Rodr\u00edguez","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jsbmb.2026.107097_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01864-y","article-title":"Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance","volume":"8","author":"Martin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jsbmb.2026.107097_bib24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000481428","article-title":"Are we ready to use ESR1 mutations in clinical practice?","volume":"12","author":"Jeselsohn","year":"2017","journal-title":"Breast Care"},{"key":"10.1016\/j.jsbmb.2026.107097_bib25","doi-asserted-by":"crossref","first-page":"14146","DOI":"10.1021\/bi9911132","article-title":"Function of estrogen receptor tyrosine 537 in hormone binding, DNA binding, and transactivation","volume":"38","author":"Yudt","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.jsbmb.2026.107097_bib26","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.12792","article-title":"Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation","volume":"5","author":"Fanning","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.jsbmb.2026.107097_bib27","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.ijrobp.2016.06.139","article-title":"Targeting estrogen receptor (ER) mutations for treatment of endocrine therapy resistance in breast cancer","volume":"96","author":"Alluri","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jsbmb.2026.107097_bib28","first-page":"447S","article-title":"Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response","volume":"9","author":"Schiff","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107097_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/172460080101600301","article-title":"Role of coactivators and corepressors in steroid and nuclear receptor signaling: potential markers of tumor growth and drug sensitivity","volume":"16","author":"Cottone","year":"2001","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.jsbmb.2026.107097_bib30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1677\/ERC-09-0285","article-title":"Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line","volume":"18","author":"Karmakar","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.jsbmb.2026.107097_bib31","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1038\/s41388-017-0042-x","article-title":"Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer","volume":"37","author":"Browne","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.jsbmb.2026.107097_bib32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.7150\/ijbs.4125","article-title":"The function of steroid receptor coactivator-1 in normal tissues and cancer","volume":"8","author":"Walsh","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.jsbmb.2026.107097_bib33","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.2147\/OTT.S245749","article-title":"SRC promotes tamoxifen resistance in breast cancer via up-regulating SIRT1","volume":"13","author":"Zhou","year":"2020","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.jsbmb.2026.107097_bib34","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023248","article-title":"The role of amplified in breast cancer 1 in breast cancer: a meta-analysis","volume":"99","author":"Hou","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.jsbmb.2026.107097_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000159267","article-title":"Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells","volume":"75","author":"Su","year":"2008","journal-title":"Oncology"},{"key":"10.1016\/j.jsbmb.2026.107097_bib36","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.onc.1207202","article-title":"Impact of the nuclear receptor coactivator AIB1 isoform AIB1-D3 on estrogenic ligands with different intrinsic activity","volume":"23","author":"Reiter","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.jsbmb.2026.107097_bib37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2020.09.017","article-title":"Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer","volume":"495","author":"Oh","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jsbmb.2026.107097_bib38","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/me.2016-1072","article-title":"Minireview: the link between ER\u03b1 corepressors and histone deacetylases in tamoxifen resistance in breast cancer","volume":"30","author":"L\u00e9gar\u00e9","year":"2016","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib39","first-page":"169","article-title":"Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation","volume":"2","author":"Wong","year":"2014","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib40","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1073\/pnas.95.6.2920","article-title":"Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes","volume":"95","author":"Lavinsky","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.jsbmb.2026.107097_bib41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1677\/erc.1.00776","article-title":"Mechanisms of tamoxifen resistance","volume":"11","author":"Ring","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.jsbmb.2026.107097_bib42","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1158\/1078-0432.CCR-17-2259","article-title":"BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen-resistant breast cancer","volume":"24","author":"Gong","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107097_bib43","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3390\/ijms21061910","article-title":"NR2F2 orphan nuclear receptor is involved in estrogen receptor alpha-mediated transcriptional regulation in luminal a breast cancer cells","volume":"21","author":"Erd\u0151s","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jsbmb.2026.107097_bib44","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3389\/fendo.2019.00733","article-title":"Nongenomic effects of estrogen on cell homeostasis and remodeling with special focus on cardiac ischemia\/reperfusion injury","volume":"10","author":"Puglisi","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s12282-008-0070-z","article-title":"Estrogen signaling pathway and hormonal therapy","volume":"15","author":"Hayashi","year":"2008","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jsbmb.2026.107097_bib46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2407-7-59","article-title":"Enhanced NF\u03baB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer","volume":"7","author":"Zhou","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jsbmb.2026.107097_bib47","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.breast.2015.07.015","article-title":"The changing role of ER in endocrine resistance","volume":"24","author":"Nardone","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.jsbmb.2026.107097_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.clbc.2016.08.004","article-title":"Consequences of the convergence of multiple alternate pathways on the estrogen receptor in the treatment of metastatic breast cancer","volume":"17","author":"Gluck","year":"2017","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.jsbmb.2026.107097_bib49","series-title":"Endogenous Factors Influencing Host-Tumor Balance","first-page":"15","article-title":"Estrogen receptors in hormone-responsive tissues and tumors","author":"Jensen","year":"1967"},{"key":"10.1016\/j.jsbmb.2026.107097_bib50","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1021\/acs.jmedchem.5b01281","article-title":"Recent progress in the discovery of next generation inhibitors of aromatase from the structure-function perspective","volume":"59","author":"Ghosh","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2026.107097_bib51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/457159a","article-title":"Anticancer drug target pictured","volume":"457","author":"Waterman","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jsbmb.2026.107097_bib52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nature07614","article-title":"Structural basis for androgen specificity and estrogen synthesis in human aromatase","volume":"457","author":"Ghosh","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jsbmb.2026.107097_bib53","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1210\/er.2008-0016","article-title":"History of aromatase: Saga of an important biological mediator and therapeutic target","volume":"30","author":"Santen","year":"2009","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jsbmb.2026.107097_bib54","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1210\/endo-92-3-866","article-title":"Studies on the mechanism of estrogen biosynthesis: VIII. The development of inhibitors of the enzyme system in human placenta","volume":"92","author":"Schwarzel","year":"1973","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2026.107097_bib55","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0022-4731(88)90129-X","article-title":"6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor","volume":"30","author":"Giudici","year":"1988","journal-title":"J. Steroid Biochem."},{"key":"10.1016\/j.jsbmb.2026.107097_bib56","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1749-6632.1990.tb34309.x","article-title":"Novel irreversible aromatase inhibitors","volume":"595","author":"di Salle","year":"1990","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jsbmb.2026.107097_bib57","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/0039-128X(95)00058-X","article-title":"Further studies on 6-Alkylandrost-4-ene-3,17-diones as aromatase inhibitors: elongation of the 6-Alkyl Chain","volume":"60","author":"Numazawa","year":"1995","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib58","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0039-128X(03)00085-0","article-title":"Structure\u2013activity relationships of 3-deoxy androgens as aromatase inhibitors. Synthesis and biochemical studies of 4-substituted 4-ene and 5-ene steroids","volume":"68","author":"Nagaoka","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib59","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0039-128X(01)00096-4","article-title":"New D-modified androstane derivatives as aromatase inhibitors","volume":"66","author":"Gasi","year":"2001","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib60","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0039-128X(03)00097-7","article-title":"Synthesis, X-ray crystal structures and biological activity of 16-amino-17-substituted-d-homo steroid derivatives","volume":"68","author":"Gasi","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.steroids.2004.10.005","article-title":"Synthesis and anti-aromatase activity of some new steroidal D-lactones","volume":"70","author":"Gasi","year":"2005","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib62","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.steroids.2008.02.006","article-title":"Synthesis and biological evaluation of some new A, B-ring modified steroidal D-lactones","volume":"73","author":"Djurendic","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib63","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.steroids.2006.10.002","article-title":"Synthesis and biological evaluation of some 17-picolyl and 17-picolinylidene androst-5-ene derivatives","volume":"72","author":"Gasi","year":"2007","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib64","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.steroids.2007.09.005","article-title":"Synthesis of some epoxy and\/or n-oxy 17-picolyl and 17-picolinylidene-androst-5-ene derivatives","volume":"73","author":"Djurendic","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib65","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bioorg.2008.01.002","article-title":"Synthesis and biological evaluation of a series of A, B-ring modified 16,17-secoandrostane derivatives","volume":"36","author":"Sakac","year":"2008","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.jsbmb.2026.107097_bib66","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.steroids.2012.02.005","article-title":"Design, synthesis and evaluation of novel 16-imidazolyl substituted steroidal derivatives possessing potent diversified pharmacological properties","volume":"77","author":"Bansal","year":"2012","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib67","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s00044-012-0059-1","article-title":"Synthesis of imidazole-derived steroidal hybrids as potent aromatase inhibitors","volume":"22","author":"Bansal","year":"2013","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.jsbmb.2026.107097_bib68","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1248\/cpb.59.327","article-title":"Synthesis and biological evaluation of 16e-arylidenosteroids as cytotoxic and anti-aromatase agents","volume":"59","author":"Bansal","year":"2011","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.jsbmb.2026.107097_bib69","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bioorg.2012.08.005","article-title":"Synthesis and aromatase inhibitory activity of some new 16E-arylidenosteroids","volume":"45","author":"Bansal","year":"2012","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.jsbmb.2026.107097_bib70","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jsbmb.2005.06.029","article-title":"Structure\u2013activity relationships of 2\u03b1-substituted androstenedione analogs as aromatase inhibitors and their aromatization reactions","volume":"97","author":"Numazawa","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib71","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.steroids.2009.06.001","article-title":"6\u03b2,19-Bridged androstenedione analogs as aromatase inhibitors","volume":"74","author":"Komatsu","year":"2009","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib72","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.steroids.2010.12.013","article-title":"Synthesis of some novel androstanes as potential aromatase inhibitors","volume":"76","author":"Yadav","year":"2011","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib73","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.steroids.2012.04.010","article-title":"Steroidal carbonitriles as potential aromatase inhibitors","volume":"77","author":"Yadav","year":"2012","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib74","doi-asserted-by":"crossref","first-page":"8464","DOI":"10.1021\/jm300930n","article-title":"Novel aromatase inhibitors by structure-guided design","volume":"55","author":"Ghosh","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2026.107097_bib75","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1021\/jm300262w","article-title":"New structure-activity relationships of A- and D-Ring modified steroidal aromatase inhibitors: design, synthesis, and biochemical evaluation","volume":"55","author":"Varela","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2026.107097_bib76","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1021\/acs.jmedchem.9b00157","article-title":"C-6\u03b1- vs C-7\u03b1-substituted steroidal aromatase inhibitors: which is better? Synthesis, biochemical evaluation, docking studies, and structure-activity relationships","volume":"62","author":"Roleira","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2026.107097_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106286","article-title":"Design, synthesis, biological activity evaluation and structure-activity relationships of new steroidal aromatase inhibitors. The case of C-Ring and 7\u03b2 substituted steroids","volume":"131","author":"Roleira","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.jsbmb.2026.107097_bib78","first-page":"408","article-title":"Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer","volume":"54","author":"DeFriend","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107097_bib79","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.3390\/ijms22157812","article-title":"Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective","volume":"22","author":"Hernando","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jsbmb.2026.107097_bib80","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1677\/joe.0.112R007","article-title":"Steroidal pure antioestrogens","volume":"112","author":"Wakeling","year":"1987","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib81","first-page":"3867","article-title":"A potent specific pure antiestrogen with clinical potential","volume":"51","author":"Wakeling","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107097_bib82","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1006132427948","article-title":"Steroid hormone receptors in breast cancer management","volume":"51","author":"Osborne","year":"1998","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2026.107097_bib83","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ijc.2910550529","article-title":"Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780","volume":"55","author":"Hu","year":"1993","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jsbmb.2026.107097_bib84","first-page":"3867","article-title":"A potent specific pure antiestrogen with clinical potential","volume":"51","author":"Wakeling","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107097_bib85","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0169-6009(08)80220-6","article-title":"Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women","volume":"22","author":"Ward","year":"1993","journal-title":"Bone Miner."},{"key":"10.1016\/j.jsbmb.2026.107097_bib86","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0969-2126(01)00568-8","article-title":"Structural insights into the mode of action of a pure antiestrogen","volume":"9","author":"Pike","year":"2001","journal-title":"Structure"},{"key":"10.1016\/j.jsbmb.2026.107097_bib87","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1128\/MCB.00290-12","article-title":"Role of SUMOylation in full antiestrogenicity","volume":"32","author":"Hilmi","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib88","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.18632\/oncotarget.24023","article-title":"ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models","volume":"9","author":"Guo","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jsbmb.2026.107097_bib89","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM phase III Trial comparing fulvestrant 250 mg with Fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib90","first-page":"2852","article-title":"Steroid sulphatase and its inhibitors: past, present, and future","volume":"25","author":"Foster","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jsbmb.2026.107097_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155844","article-title":"Contribution of estrone sulfate to cell proliferation in aromatase inhibitor (AI)-resistant, hormone receptor-positive breast cancer","volume":"11","author":"Higuchi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jsbmb.2026.107097_bib92","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/0006-2952(90)90115-2","article-title":"Sulfate derivatives of 2-phenylindoles as novel steroid sulfatase inhibitors. An in vitro study on structure-activity-relationship","volume":"39","author":"Birnbock","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib93","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0960-0760(91)90243-X","article-title":"Inhibition of estrone sulfatase enzyme in human placenta and human breast carcinoma","volume":"39","author":"Evans","year":"1991","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib94","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0960-0760(94)90203-8","article-title":"Inhibition of steroid sulphatase activity by steroidal methylthiophosphonates: potential therapeutic agents in breast cancer","volume":"48","author":"Purohit","year":"1994","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib95","first-page":"298","article-title":"Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer","volume":"53","author":"Duncan","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107097_bib96","doi-asserted-by":"crossref","first-page":"14801","DOI":"10.1021\/bi020543g","article-title":"Estrone 3-sulfate mimics, inhibitors of estrone sulfatase activity: homology model construction and docking studies","volume":"41","author":"Howarth","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.jsbmb.2026.107097_bib97","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0039-128X(96)00243-7","article-title":"Estrone sulfonates as inhibitors of estrone sulfatase","volume":"62","author":"Howarth","year":"1997","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib98","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0039-128X(93)90045-O","article-title":"Synthesis and biochemical studies of estrone sulfatase inhibitors","volume":"58","author":"Li","year":"1993","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib99","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1021\/bi961536t","article-title":"Estrone sulfatase: probing structural requirements for substrate and inhibitor recognition","volume":"36","author":"Anderson","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.jsbmb.2026.107097_bib100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1749-6632.1996.tb16226.x","article-title":"Regulation and inhibition of steroid sulfatase activity in breast cancer","volume":"784","author":"Purohit","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jsbmb.2026.107097_bib101","doi-asserted-by":"crossref","first-page":"11508","DOI":"10.1021\/bi00036a025","article-title":"Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-o-sulfamate","volume":"34","author":"Purohit","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.jsbmb.2026.107097_bib102","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1021\/jm00028a002","article-title":"Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential","volume":"37","author":"Howarth","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2026.107097_bib103","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0960-0760(95)00214-6","article-title":"Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application","volume":"55","author":"Elger","year":"1995","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib104","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0960-894X(03)00009-X","article-title":"Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II","volume":"13","author":"Vicker","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jsbmb.2026.107097_bib105","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0006-291X(03)00865-9","article-title":"Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates","volume":"305","author":"Ho","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jsbmb.2026.107097_bib106","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0960-0760(97)00196-9","article-title":"The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulfatase inhibitors with reduced oestrogenicity","volume":"64","author":"Purohit","year":"1998","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2026.107097_bib107","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.bmc.2012.03.007","article-title":"Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors","volume":"20","author":"Woo","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jsbmb.2026.107097_bib108","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0039-128X(98)00044-0","article-title":"Development of potent non-estrogenic estrone sulfatase inhibitors","volume":"63","author":"Li","year":"1998","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107097_bib109","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0968-0896(03)00042-7","article-title":"D-Ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase","volume":"11","author":"Fischer","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jsbmb.2026.107097_bib110","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.steroids.2010.05.011","article-title":"4- and 6-(P-sulphamoylphenyl) androstenediones: studies of aromatase inhibitor-based oestrone sulphatase inhibition","volume":"75","author":"Watari","year":"2010","journal-title":"Steroids"}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076026001639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076026001639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:27:47Z","timestamp":1791354467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076026001639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":110,"alternative-id":["S0960076026001639"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2026.107097","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of steroidal molecules for targeted breast cancer therapy: Endocrine resistance and innovative drug design","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2026.107097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107097"}}